Внебольничная пневмония у пациентов пожилого и старческого возраста
https://doi.org/10.18093/0869-0189-2015-25-3-261-276
Аннотация
Внебольничная пневмония (ВП) – одно из наиболее часто встречающихся инфекционных заболеваний в развитых странах. Хроническая сердечная недостаточность (ХСН) является независимым фактором риска неблагоприятного течения и прогноза при ВП. Необходимость более широкого использования в рутинной практике мультиспиральной компьютерной томографии органов грудной клетки и определения сывороточных биомаркеров воспаления обусловлена объективными трудностями клинической, рентгенологической, лабораторной и микробиологической диагностики ВП у пациентов пожилого и старческого возраста с ХСН. Системная антибактериальная терапия у данной категории больных проводится в соответствии с общепринятыми стандартами. Однако рассматриваемая популяция пациентов является гетерогенной, поэтому при разработке персонализированного подхода к терапии должны учитываться различные факторы риска.
Об авторах
А. А. Бобылев
ГБОУ ВПО «Смоленский государственный медицинский университет» Минздрава России: 214019, Смоленск, ул. Крупской, 28;
Россия
Россия
к. м. н., ассистент кафедры клинической фармакологии ГБОУ ВПО «Смоленский государственный медицинский университет» Минздрава России; тел.: (4812) 61-13-01;
С. А. Рачина
Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии: 214019, Смоленск, ул. Кирова, 46а;
Россия
Россия
д. м. н., руководитель отдела фармакоэкономики и фармакоэпидемиологии Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии; тел.: (4812) 45-06-02
С. Н. Авдеев
ФГБУ «НИИ пульмонологии» ФМБА России: 105077, Москва, ул. 11-я Парковая, 32, корп. 4
Россия
Россия
д. м. н., профессор, руководитель клинического отдела ФГБУ "НИИ пульмонологии" ФМБА России; тел.: (495) 465-52-64;
Р. С. Козлов
ГБОУ ВПО «Смоленский государственный медицинский университет» Минздрава России: 214019, Смоленск, ул. Крупской, 28;
Россия
Россия
д. м. н., профессор, директор НИИ антимикробной химиотерапии ГБОУ ВПО "Смоленский государственный медицинский университет" Минздрава России; тел.: (4812) 45-06-02;
Н. Н. Дехнич
ГБОУ ВПО «Смоленский государственный медицинский университет» Минздрава России: 214019, Смоленск, ул. Крупской, 28;
Россия
Россия
к. м. н., ассистент кафедры факультетской терапии ГБОУ ВПО "Смоленский государственный медицинский университет" Минздрава России; тел.: (4812) 27-11-06;
Список литературы
1. Trotter C.L., Stuart J.M., George R., Miller E. Increasing hospital admissions for pneumonia, England. Emerg. Infect. Dis. 2008; 14 (5): 727–733.
2. Чучалин А.Г. Клинические рекомендации. Пульмонология. М.: ГЭОТАР-Медиа; 2005.
3. Чучалин А.Г. Респираторная медицина. М.: ГЭОТАР-Медиа; 2007.
4. Torres A., Peetermans W.E., Viegi G. et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013; 68 (11):1057–1065.
5. Brown J.S. Community-acquired pneumonia. Clin. Med. 2012; 12 (6): 538–643.
6. Steel H.C., Cockeran R., Anderson R. et al. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013; 2013: 490346.
7. Gau J., Acharya U., Khan S. et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr. 2010; 10: 45.
8. Sopena N., Pedro-Botet L., Mateu L. et al. Community-acquired legionella pneumonia in elderly patients: characteristics and outcome. J. Am. Geriatr. Soc. 2007; 55 (1): 114–119.
9. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007; 93 (9): 1137–1146.
10. Thomsen R.W., Riis A., Nørgaard M. et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J. Intern. Med. 2006; 259: 410–417.
11. Thomsen R.W., Kasatpibal N., Riis A. et al. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J. Gen. Intern. Med. 2008; 23 (9): 1407–1413.
12. Jackson M.L., Neuzil K.M., Thompson W.W. et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. 2004, 39: 1642–1650.
13. Piazza G., Seddighzadeh A., Goldhaber S.Z. Heart failure in patients with deep vein thrombosis. Am. J. Cardiol. 2008; 101 (7): 1056–1059.
14. Xiao K., Su L.X., Han B.C. et al. Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. J. Thorac. Dis. 2013; 5 (5): 626–633.
15. Ishiguro T., Takayanagi N., Yamaguchi S. et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern. Med. 2013; 52 (3): 317–324.
16. García-Vázquez E., Soto S., Gómez J. et al. Simple criteria to assess mortality in patients with community-acquired pneumonia. Med. Clin. (Barc.). 2008; 131 (6): 201–204.
17. Corrales-Medina V.F., Musher D.M., Wells G.A. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012; 125 (6): 773–781.
18. Kondo A., Morinaga Y., Sasaki E. et al. Prognostic and risk factors in patients hospitalized with bacterial pneumonia. Kansenshogaku Zasshi. 2007; 81 (3): 268–275.
19. Welte T. Community-acquired pneumonia. Internist (Berl.). 2009; 50 (3): 331–339.
20. Welte T., Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin. Respir. Crit. Care Med. 2009; 30 (2): 127–135.
21. Fujiki R., Kawayama T., Ueyama T. et. al. The risk factors for mortality of community-acquired pneumonia in Japan. J. Infect. Chemother. 2007; 13 (3): 157–165.
22. Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243–250.
23. Lim W.S., van der Eerden M.M., Laing R. et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58: 377–382.
24. Liu L. Changes in cardiovascular hospitalization and comorbidity of heart failure in the United States: findings from the National Hospital Discharge Surveys 1980–2006. Int. J. Cardiol. 2011; 149 (1): 39–45.
25. Dai S., Walsh P., Wielgosz A. et al. Comorbidities and mortality associated with hospitalized heart failure in Canada. Can. J. Cardiol. 2012; 28 (1): 74–79.
26. Pei Z.Y., Zhao Y.S., Li J.Y. et al. Fifteen-year evolving trends of etiology and prognosis in hospitalized patients with heart failure. Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39 (5): 434–439.
27. Viasus D., Garcia-Vidal C., Manresa F. et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J. Infect. 2013; 66 (1): 27–33.
28. Musher D.M., Rueda A.M., Kaka A.S. et al. The association between pneumococcal pneumonia and acute cardiac events. Clin. Infect. Dis. 2007; 45 (2): 158–165.
29. Becker T., Moldoveanu A., Cukierman T. et al. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabet. Res. Clin. Pract. 2007; 78: 392–397.
30. Ramirez J., Aliberti S., Mirsaeidi M. et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin. Infect. Dis. 2008; 47: 182–187.
31. Perry T.W., Pugh M.J., Waterer G.W. et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am. J. Med. 2011; 124: 244–251.
32. Mandal P., Chalmers J.D., Choudhury G. et al. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM. 2011; 104: 489–495.
33. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клиническая микробиология и антимикробная химиотерапия. 2006; 8 (1): 54–86.
34. Maisel A., Neath S.X., Landsberg J. et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur. J. Heart Fail. 2012; 14 (3): 278–286.
35. Mueller C., Scholer A., Laule-Kilian K. et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 2004; 350: 647–654.
36. Dickstein K., Cohen-Solal A., Filippatos G. et al. The Task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 2008; 29: 2388–2442.
37. Schneider H.G., Lam L., Lokuge A. et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann. Intern. Med. 2009; 150 (6): 365–371.
38. Villacorta H., Duarte A., Duarte N.M. et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Arq. Bras. Cardiol. 2002; 79 (6): 569–572, 564–568.
39. American Thoracic Society. ATS Statement: Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–117.
40. Deboeck G., Muylem A.V., Vachiéry J.L., Naeije R. Physiological response to the 6-minute walk test in chronic heart failure patients versus healthy control subjects. Eur. J. Prev. Cardiol. 2013; 21 (8): 997–1003.
41. José A., Corso S.D. Patients hospitalized for community-acquired pneumonia present reduced functional performance. Braz. J. Phys. Ther. 2013; 17 (4): 351–358.
42. Chong C.P., Street P.R. Pneumonia in the elderly: A review of the epidemiology, pathogenesis, microbiology, and clinical features. South Med. J. 2008; 101: 1141–1145.
43. Fung H.B., Monteagudo-Chu M.O. Community-acquired pneumonia in the elderly. Am. J. Geriatr. Pharmacother. 2010; 8 (1): 47–62.
44. Mor A., Thomsen R.W., Ulrichsen S.P. et al. Chronic heart failure and risk of hospitalization with pneumonia: A population-based study. Eur. J. Intern. Med. 2013; 24: 349–353.
45. Ware L.B., Matthay M.A. Clinical practice. Acute pulmonary edema. N. Engl. J. Med. 2005; 353: 2788–2796.
46. Marik P.E., Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest. 2003; 124: 328–336.
47. Sura L., Madhavan A., Carnaby G. et al. Dysphagia in the elderly: management and nutritional considerations. Clin. Interv. Aging. 2012; 7: 287–298.
48. Janssens J.P., Krause K.H. Pneumonia in the very old. Lancet Infect. Dis. 2004; 4: 112–124.
49. Zalacain R., Torres A., Celis R. et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur. Respir. J. 2003; 21: 294–302.
50. Kaplan V., Angus D.C. Community-acquired pneumonia in the elderly. Crit. Care Clin. 2003; 19: 729–748.
51. Bobylev A.A., Rachina S.A., Kozlov R.S., Belkova Y.A. Assessment of serum C-reactive protein level to improve community-acquired pneumonia diagnostics in patients with chronic heart failure. In: Proceedings of 25th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, 25–28 Apr. 2015: 1436.
52. Gutiérrez F., Masiá M. Improving outcomes of elderly patients with community-acquired pneumonia. Drugs Aging. 2008; 25 (7): 585–610.
53. Gutiérrez F., Masiá M. Rodriguez J.C. et al. Epidemiology of community-acquired pneumonia at the dawn of the twenty first century: a prospective study on the Mediterranean coast of Spain. Clin. Microbiol. Infect. 2005; 11: 788–800.
54. Kaplan V., Angus D.C., Griffin M.F. et al. Hospitalized community-acquired pneumonia in the elderly: Age- and sex-related patterns of care and outcome in the United States. Am. J. Respir. Crit. Care Med. 2002; 165: 766–772.
55. Woods G.L., Isaacs R.D., McCarroll K.A. et al. Ertapenem therapy for community-acquired pneumonia in the elderly. J. Am. Geriatr. Soc. 2003; 51: 1526–1532.
56. Vila-Corcoles A., Ochoa-Gondar O., Rodriguez-Blanco T. et al., for the EPIVAC Study Group. Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respir. Med. 2009; 103: 309–316.
57. El-Solh A.A., Pietrantoni C., Bhat A. et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am. J. Respir. Crit. Care Med. 2003; 167: 1650–1654.
58. Lieberman D., Lieberman D. Community-acquired pneumonia in the elderly: A practical guide to treatment. Drugs Aging. 2000; 17: 93–105.
59. Garcia-Vazquez E., Marcos M.A., Mensa J. et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch. Intern. Med. 2004; 164: 1807–1811.
60. Niederman M.S., Ahmed Q.A. Community-acquired pneumonia in elderly patients. Clin. Geriatr. Med. 2003; 19: 101–120.
61. Gutiérrez F., Masiá M., Rodriguez J.C. et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin. Infect. Dis. 2003; 36: 286–292.
62. Murdoch D.R. Diagnosis of Legionella infection. Clin. Infect. Dis. 2003; 36: 64–69.
63. Bellei N., Benfica D., Perosa A.H. et al. Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J. Virol. Methods. 2003; 109: 85–88.
64. Murdoch D.R., Laing R.T., Mills G.D. et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J. Clin. Microbiol. 2001; 39: 3495–3498.
65. Rodriguez J.C., Masiá M., Gutiérrez F. et al. Legionella pneumophila in community acquired pneumonia: interpretation of microbiological techniques (in Spanish). Med. Clin. (Barc.). 2004; 122: 277–278.
66. Monto A.S., Gravenstein S., Elliott M. et al. Clinical signs and symptoms predicting influenza infection. Arch. Intern. 2000; 160: 3243–3247.
67. Waterer G.W., Wunderink R.G. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir. Med. 2001; 95: 78–82.
68. Yu V.L., Chiou C.C., Feldman C. et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 2003; 37: 230–237.
69. Campbell S.G., Marrie T.J., Anstey R. et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest. 2003; 123: 1142–1150.
70. Houck P.M., Bratzler D.W., Nsa W. et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 2004; 164: 637–644.
71. Mandell L.A., Wunderink R.G, Anzueto A. et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44: 27–72.
72. Paganin F., Lilienthal F., Bourdin A. et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur. Respir. J. 2004; 24: 779–785.
73. Metersky M.L., Ma A., Bratzler D.W. et al. Predicting bacteremia in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2004; 169: 342–347.
74. Saito A., Kohno S., Matsushima T. et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J. Infect. Chemother. 2006; 12: 63–69.
75. García-Ordóñez M.A., García-Jiménez J.M., Páez F. et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 14–19.
76. El-Solh A.A., Sikka P., Ramadan F. et al. Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care Med. 2001; 163 (3, Pt 1): 645–651.
77. Gutiérrez F., Masiá M., Mirete C. et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J. Infect. 2006; 53 (3): 166–174.
78. Kanwar M., Brar N., Khatib R. et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest. 2007; 131 (6): 1865–1869.
79. Basi S.K., Marrie T.J., Huang J.Q. et al. Patients admitted to hospital with suspected pneumonia and normal chest radiography. Epidemiology, microbiology and outcomes. Am. J. Med. 2004; 117: 305–311.
80. Loeb M.B., Carusone S.B., Marrie T.J. et al. Interobserver reliability of radiologists interpretations of mobile chest radiographs for nursing home-acquired pneumonia. J. Am. Med. Dir. Assoc. 2006; 7: 416–419.
81. Albaum M.N., Hill L.C., Murphy M. et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. Chest. 1996; 110: 345–350.
82. Müller B., Harbarth S., Stolz D. et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis. 2007; 7: 10. DOI:10.1186/1471-2334-7-10.
83. Castro-Guardiola A., Armengou-Arxe A., Viejo-Rodriguez A. et al. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur. J. Intern. Med. 2000; 11: 334–339.
84. Lee Y.J., Lee J., Park Y.S. et al. Predictors of cardiogenic and non-cardiogenic causes in cases with bilateral chest infiltrates. Tuberc. Respir. Dis. (Seoul). 2013; 74: 15–22.
85. Israel H.L., Weiss W., Eisenberg G.M. et al. Delayed resolution of pneumonias. Med. Clin. N. Am. 1956; 40: 1291–1303.
86. Ali A., El Solh A.A., Alan T. et al. Radiographic Resolution of Community-Acquired Bacterial Pneumonia in the Elderly. J. Am. Geriatr. Soc. 2004; 52 (2): 224–229.
87. Severs D., Moolenaar C., van Genderen P. Value of routine chest radiography in the diagnostic work-up of ill returned travelers. Intern. J. General Med. 2012; 5: 1003–1008.
88. Madelon F.E., Paling E.P., Hoepelman A.I.M. et al. Evaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review. BMC Fam. Pract. 2012; 29: 383–393.
89. Holm A., Nexoe J., Bistrup L.A. et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br. J. Gen. Pract. 2007; 57: 547–554.
90. Macfarlane J., Holmes W., Gard P. et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001; 56: 109–114.
91. José V., Domingo M.L., Soto C. et al. Radiology of bacterial pneumonia. Eur. J. Radiol. 2004; 51: 102–113.
92. Tanaka N., Matsumoto T., Kuramitsu T. et al. High resolution CT findings in community-acquired pneumonia. J. Comput. Assist. Tomogr. 1996; 20: 600–608.
93. Wheeler J.H., Fishman E.K. Computed tomography in the management of chest infections: current status. Clin. Infect. Dis. 1996; 23: 232–240.
94. Syrjälä H., Broas M., Suramo I. et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin. Infect. Dis. 1998; 27: 358–363.
95. Volpicelli G., Cardinale L., Berchialla P. et al. A comparison of different diagnostic tests in the bedside evaluation of pleuritic pain in the ED. Am. J. Emerg. Med. 2012; 30 (2): 317–324.
96. Esayag Y., Nikitin I., Bar-Ziv J. et al. Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia. Am. J. Med. 2010; 123 (1): 88.e1–88.e6.
97. Boyd A.R., Orihuela C.J. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis. 2011; 2 (6): 487–500.
98. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Dan. Med. Bull. 2006; 53 (3): 285–309.
99. Kelly E., MacRedmond R.E., Cullen G. et al Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia? Respirology. 2009; 14: 210–216.
100. Joffe E., Justo D., Mashav N. et al. C-reactive protein to distinguish pneumonia from acute decompensated heart failure. Clin. Biochem. 2009; 42 (16–17): 1628–1634.
101. Maruyama T., Gabazza E.C., Morser J. et al. Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir. Med. 2010; 104 (4): 584–592.
102. Coelho L.M., Salluh J.I., Soares M. et al. Patterns of С-reactive protein RATIO response in severe community–acquired pneumonia: a cohort study. Crit. Care. 2012; 16 (2): R53.
103. Lacoma A., Rodríguez N., Prat C. et al. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31 (5): 825–833.
104. Menéndez R., Sahuquillo-Arce J.M., Reyes S. et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest. 2012; 141 (6): 1537–1545.
105. Berg P., Lindhardt B.Ø. The role of procalcitonin in adult patients with community-acquired pneumonia – a systematic review. Dan. Med. J. 2012; 59 (3): A4357.
106. Almirall J., Bolíbar I., Toran P. et al. Community-Acquired Pneumonia Maresme Study Group. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004; 125 (4): 1335–1342.
107. Cals J.W., Butler C.C., Hopstaken R.M. et al. Effect of point of care testing for C-reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. Br. Med. J. 2009; 338: 1112–1116.
108. Krüger S., Ewig S., Giersdorf S. et al. German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am. J. Respir. Crit. Care Med. 2010; 182 (11): 1426–1434.
109. Schuetz P., Wolbers M., Christ-Crain M. et al.; ProHOSP Study Group. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit. Care. 2010; 14 (3): R106.
110. Schuetz P., Suter-Widmer I., Chaudri A. et al. Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur. Respir. J. 2011; 37 (2): 384–392.
111. Christ-Crain M., Stolz D., Bingisser R. et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 2006; 174 (1): 84–93.
112. Schuetz P., Batschwaroff M., Dusemund F. et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur. J. Clin. Microbiol. Infect. Dis. 2010; 29 (3): 269–277.
113. Tang H., Huang T., Jing J. et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009; 37 (6): 497–507.
114. Meehan T.P., Fine M.J., Krumholz H.M. et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997; 278: 2080–2084.
115. Benenson R., Magalski A., Cavanaugh S. et al. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med. 1999; 6: 1243–1248.
116. Marrie T.J., Wu L. Factors influencing in hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005; 127: 1260–1270.
117. Gleason P.P., Meehan T.P., Fine J.M. et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999; 159: 2562–2572.
118. Houck P.M., MacLehose R.F., Niederman M.S. et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001; 119: 1420–1426.
119. Grossman R.F., Campbell D.A., Landis S.J. et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J. Antimicrob. Chemother. 1999; 43 (4): 549–554.
120. Wilson B.Z., Anzueto A., Restrepo M.I. et al. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit. Care Med. 2012; 40 (8): 2310–2314.
121. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике: Пособие для врачей. М.: РРО, МАКМАХ; 2010.
122. Romanelli G., Cravarezza P., Pozzi A. et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J. Chemother. 2002; 14 (6): 609–617.
123. Bradley J.S., Garau J. Lode H. et al. Carbapenems in clinical practice: a guide to their use in serious infection. Intern. Int. J. Antimicrob. Agents. 1999; 11 (2): 93–100.
124. Murcia J.M., Gonzalez-Comeche J., Marin A. et al. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin. Microbiol. Infect. 2009; 15: 1046–1050.
125. Yanagihara K., Fukuda Y., Seki M. et al. Clinical comparative study of sulbactam / ampicillin and imipenem / cilastatin in elderly patients with communityacquired pneumonia. Intern. Med. 2006; 45 (17): 995–999. DOI: 10.2169/internalmedicine.45.1717.
126. Shorr A.F., Zadeikis N., Xiang J.X. et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥ 65 years with community-acquired pneumonia. Clin. Ther. 2005; 27: 1251–1259.
127. Finch R., Schurmann D., Collins O. et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 2002; 46 (6): 1746–1754.
128. Correa J.C., Badaro R., Bumroongkit C. et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin. Ther. 2003; 25 (5): 1453–1468.
129. Frank E., Liu J., Kinasewitz G. et al. A multicenter, openlabel, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther. 2002; 24 (8): 1292–1308.
130. Vardakas K.Z., Siempos I.I., Grammatikos A. et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ. 2008; 179 (12): 1269–1277.
131. Ye X., Sikirica V., Schein J.R. et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin. Ther. 2008; 30 (2): 358–371.
132. Anzueto A., Niederman M.S., Pearle J. et al. Community-Aquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis. 2006; 42: 73–81.
133. Dong K., Quan D.J. Appropriately assessing renal function for drug dosing. Nephrol. Nurs. J. 2010; 37 (3): 304–308.
134. Murphree D.D., Thelen S.M. Chronic kidney disease in primary care. J. Am. Board. Fam. Med. 2010; 23 (4): 542–550.
135. Olyaei A.J., Bennett W.M. Drug dosing in the elderly patients with chronic kidney disease. Clin. Geriatr. Med. 2009; 25 (3): 459–527.
136. Herring A.R., Williamson J.C. Principles of antimicrobial use in older adults. Clin. Geriatr. Med. 2007; 23 (3): 481–497.
137. Faulkner C.M., Cox H.L., Williamson J.C. Unique aspects of antimicrobial use in older adults. Clin. Infect. Dis. 2005; 40 (7): 997–1004.
138. Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Exp. Opin. Pharmacother. 2006; 7 (6): 639–651.
139. Rubinstein E., Camm G. Cardiotoxicity of fluoroquinolones. J. Antimicrob. Chemother. 2002; 49: 593–596.
140. Andriole V.T., Haverstock D.C., Choudhri S.H. et al. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Safety. 2005; 28 (5): 443–452.
141. Ferrara A.M. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Clin. Intervent. Aging. 2007; 2 (2): 179–187.
142. Russo V., Puzio G., Siniscalchi N. et al. Azithromycin-induced QT prolongation in elderly patient. Acta. Biomed. 2006; 77 (1): 30–32.
143. Morganroth J., DiMarco J.P., Anzueto A. et al. Randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest. 2005; 128: 3398–3406.
144. González-Castillo J., Martín-Sánchez F.J., Llinares P. et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev. Esp. Quimioter. 2014; 27 (1): 69–86.
Рецензия
Для цитирования:
Бобылев А.А., Рачина С.А., Авдеев С.Н., Козлов Р.С., Дехнич Н.Н. Внебольничная пневмония у пациентов пожилого и старческого возраста. Пульмонология. 2015;25(3):261-276. https://doi.org/10.18093/0869-0189-2015-25-3-261-276
For citation:
Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S., Dekhnich N.N. Community-acquired pneumonia in elderly and very elderly patients. PULMONOLOGIYA. 2015;25(3):261-276. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-3-261-276
Просмотров:
2076
Послать статью по эл. почте 